DDInter1793 DDInter1607
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Thiethylperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Magnesium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Sucralfate {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sotalol
Sotalol {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicardipine
Nicardipine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pregabalin
Pregabalin {u} (Compound) causes {v} (Side Effect) Candida infection
Candida infection {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Trospium {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linezolid
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Ipratropium {u} (Compound) downregulates {v} (Gene) NT5DC2
NT5DC2 {u} (Gene) is downregulated by {v} (Compound) Ritonavir
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Ritonavir (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin and Pregabalin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Ritonavir (Compound)